1. A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab. Issue 1 (12th March 2020) Authors: Olson, Daniel J; Rajagopal, Padma; Tjota, Melissa Y; Venkataraman, Girish; Luke, Jason J; Gajewski, Thomas F Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265). (4th November 2015) Authors: Long, Georgina V; Dummer, Reinhard; Ribas, Antoni; Puzanov, Igor; Michielin, Olivier; VanderWalde, Ari; Andtbacka, Robert HI; Cebon, Jonathan; Fernandez, Eugenio; Malvehy, Josep; Olszanski, Anthony J; Gajewski, Thomas F; Kirkwood, John M; Kuznetsova, Olga; Chen, Lisa; Kaufman, David R; Chou, Jeff... Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. Issue 1 (27th June 2013) Authors: Geynisman, Daniel M; Zha, Yuanyuan; Kunnavakkam, Rangesh; Aklilu, Mebea; Catenacci, Daniel VT; Polite, Blase N; Rosenbaum, Cara; Namakydoust, Azadeh; Karrison, Theodore; Gajewski, Thomas F; Kindler, Hedy L Journal: Journal for immunotherapy of cancer Issue: Volume 1:Issue 1(2013) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment. (4th November 2015) Authors: Horton, Brendan; Williams, Jason B; Spranger, Stefani; Gajewski, Thomas F Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. Issue 6 (22nd June 2022) Authors: Rouhani, Sherin Juliet; Yu, Jovian; Olson, Daniel; Zha, Yuanyuan; Pezeshk, Apameh; Cabanov, Alexandra; Pyzer, Athalia R; Trujillo, Jonathan; Derman, Benjamin A; O'Donnell, Peter; Jakubowiak, Andrzej; Kindler, Hedy L; Bestvina, Christine; Gajewski, Thomas F Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 6(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Characterization of oncogenic pathways linked with T cell exclusion in urothelial bladder cancer. (4th November 2015) Authors: Sweis, Randy F; Spranger, Stefani; Luke, Jason J; Gajewski, Thomas F Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Density of immunogenic antigens does not explain presence or absence of the T cell-inflamed tumor microenvironment in metastatic melanoma. (4th November 2015) Authors: Zha, Yuanyuan; Spranger, Stefani; Hernandez, Kyle M; Li, Yan; Bao, Riyue; Alexieff, Peter; Andrade, Jorge; Luke, Jason J; Gajewski, Thomas F Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. (4th November 2015) Authors: Harvey, Christopher; Elpek, Kutlu; Duong, Ellen; Simpson, Tyler; Shu, ChengYi J; Shallberg, Lindsey; Wallace, Matthew; Sathyanarayanan, Sriram; Mabry, Robert; Briskin, Michael; Michaelson, Jennifer; Gajewski, Thomas F Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Issue 8 (August 2019) Authors: Long, Georgina V; Dummer, Reinhard; Hamid, Omid; Gajewski, Thomas F; Caglevic, Christian; Dalle, Stephane; Arance, Ana; Carlino, Matteo S; Grob, Jean-Jacques; Kim, Tae Min; Demidov, Lev; Robert, Caroline; Larkin, James; Anderson, James R; Maleski, Janet; Jones, Mark; Diede, Scott J; Mitchell, Tara C Journal: Lancet oncology Issue: Volume 20:Issue 8(2019) Page Start: 1083 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Extremely potent immunotherapeutic activity of a STING agonist in the B16 melanoma model in vivo. (7th November 2013) Authors: Corrales, Leticia; Woo, Seng-Ryong; Gajewski, Thomas F Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗